Lis Jappour Autran

Lis Jappour Autran

Auto-generated profile, based on publicly available information

Lis Jappour Autran

Laboratory of Experimental Pharmacology - LAFE, Department of Physiology and Pharmacology, Biomedical Institute, Fluminense Federal University (UFF), Niteroi, RJ, Brazil; Postgraduate Program in Biomedical Sciences (Physiology and Pharmacology). Fluminense Federal University (UFF), Niteroi, RJ, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2026 in Chemico-Biological Interactions
Verified
Journal Article
Open access
AMAna Beatriz Araújo Mendes
Ana Beatriz Araújo Mendes
NMNadia Alice Vieira Motta
Nadia Alice Vieira Motta
GLGabriel Ferreira Lima
Gabriel Ferreira Lima
LALis Jappour Autran
Lis Jappour Autran
SBStephani Correia Brazão
Stephani Correia Brazão
FBFernanda Carla Ferreira Brito
Fernanda Carla Ferreira Brito
The Lancet Commission on pollution and health reported that pollution was responsible for 9 million premature deaths in 2015, making it the world's largest environmental risk factor for disease and premature death. Among environmental pollutants, tributyltin (TBT), a biocide extensively used since the 1960s in antifouling paints, fungicides, and plastic stabilizers, is recognized as one of the most hazardous anthropogenic compounds due to its persistence and bio accumulative potential. Cardiovascular diseases are leading causes of morbidity and mortality worldwide, and exposure to environmental contaminants, like TBT, has been identified as an important risk factor. While previous studies have shown that TBT induces vascular dysfunction and increases oxidative stress and inflammation in aortic tissue, its direct effects on cardiac structure and molecular signaling remain poorly understood. Given known sex-related differences in cardiovascular physiology and disease susceptibility, this study aimed to investigate the effects of subacute TBT exposure on cardiac morphology, function and molecular pathways associated with oxidative stress and inflammation in male and female Wistar rats. Animals were randomly divided into two groups: control (C) and TBT-exposed groups (1000 ng/kg/day, for 30 days). TBT exposure increased malondialdehyde levels and disrupted antioxidant enzyme expression on both sexes, with sex-specific differences. NF-κB and IkB-α had increased protein expression in both sexes, and in males iNOS expression was also increased. In females, TBT induced morphological alterations, including reduced cardiomyocyte diameter and increased interventricular septum thickness and left atrial diameter. These findings demonstrate that subacute TBT exposure exerts cardiotoxic effects through mechanisms involving oxidative stress and inflammation, with distinct sex-specific responses.

22 February 2021 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Closed access
PDF file
SBStephani Correia Brazão
Stephani Correia Brazão
LALis Jappour Autran
Lis Jappour Autran
RLRosane de Oliveira Lopes
Rosane de Oliveira Lopes
CSCHRISTIANNE BRETAS VIEIRA SCARAMELLO
CHRISTIANNE BRETAS VIEIRA SCARAMELLO
FBFernanda Carla Ferreira de Brito
Fernanda Carla Ferreira de Brito
NMNadia Alice Vieira Motta
Nadia Alice Vieira Motta
Chloroquine (CQ) and Hydroxychloroquine (HCQ) are antimalarial drugs, with anti-inflammatory properties that justify their use in the treatment of systemic lupus erythematosus and rheumatic diseases. A pandemic caused by the new coronavirus led the entire world’s scientific community to look for drugs already available on the market, capable of exercising beneficial actions in the fight against the disease. Preliminary studies in patients, as well as in vitro studies, suggested possible therapeutic effects associated with the use of HCQ and [...] Abstract Chloroquine (CQ) and Hydroxychloroquine (HCQ) are antimalarial drugs, with anti-inflammatory properties that justify their use in the treatment of systemic lupus erythematosus and rheumatic diseases. A pandemic caused by the new coronavirus led the entire world’s scientific community to look for drugs already available on the market, capable of exercising beneficial actions in the fight against the disease. Preliminary studies in patients, as well as in vitro studies, suggested possible therapeutic effects associated with the use of HCQ and